The authors concluded that further investigation is needed to understand clinical relevance, but it is tempting to speculate that SGLT2 inhibitors may confer part of their anti-T2DM effect in this way [93]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.